Biliary Cancer
TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
- Details
ClinicalTrials.gov ID:
NCT05727176
Diagnosis Type:
NA
USOR Number:
- Address
,
P: